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Abstract 
In patients with symptomatic carotid artery stenosis is convincing evidence 
that carotid endarterectomy (CEA) confers maximum benefit if performed 
within 14 days from index event. Patients with TIA or minor stroke have 
an increased risk of early recurrent stroke in the first weeks after the index 
event, then declining over months. This is the rationale to perform CEA as 
soon as possible after an index event. However, the procedural risk within 
the urgent time period is unknown. 
 
Aim 
The overall aim of this thesis was to investigate the optimal timing of 
surgical treatment in patients with symptomatic carotid stenosis. 
 
Methods 
In study I, registry data, obtained from Swedvasc, was analyzed regarding 
procedural risk of CEA, stratified for delay from index event. Mortality 
and stroke rate was studied at four time points, 0-2 days, 3-7 days, 8-14 
days and 15-180 days. A multivariable analysis was performed to find 
other risk factors for CEA than time from referring event. 
In study II, 397 patients from WINGA, a region based registry for 
ultrasound investigations, were analyzed. All included patient had a 
significant symptomatic carotid stenosis. The risk of recurrent stroke at 
day 2, 7 and 30 after the index event was analyzed. 
Study III, was a prospective population based study with 418 consecutive 
patients comparing CEA within 48 hours with CEA after 48 hours to 14 
days from most recent event. Primary endpoint was 30 days stroke and/or 
mortality rate after CEA.  
Study IV, included all CEA for symptomatic carotid stenosis registered in 
Swedvasc from May, 2008 to October, 2014. All medical records for CEA 
performed within 2 days were collected, and also a control group with CEA 
3 to 7 days from index event. Analysis of validated and crude data 
regarding procedural risk stratified for delay was made. 
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Results 
The overall results from the four studies in the thesis shows an early risk 
of recurrent stroke at 1.7-2.0% day 2, 4% at one week and 7.5% at day 30. 
The procedural risk was 7.3-11.5% when CEA was performed within 2 
days, 2.9-3.6% in patients with CEA 3 to 7 days, and 3.0-5.0% if surgery 
was performed 3 to 14 days after index event. 
 
Conclusions 
In summary, the procedural risk exceeds the risk of recurrent stroke day 0 
to 2 in the studies in this thesis. The procedural risk, when 48 hours have 
elapsed after index event are not associated with an increased risk 
compared to even later surgery. This advocate a more expedited 
intervention than today’s guidelines recommend. The exception should be 
day 0 and 1, where only a minority of patients benefit from surgery. 
 
 
Keywords 
Carotid artery stenosis, carotid endarterectomy, stroke, transient ischemic 
attack, ocular transient ischemic attack 
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Sammanfattning på svenska 
Cirka 22 000 personer får stroke varje år i Sverige. Tiotusen personer dör i Sverige 
varje år till följd av stroke. Det är den sjukdomsgrupp som behöver flest vårddygn. 
Cirka 85 % av alla stroke beror på hjärninfarkt och cirka 10 % av dem är orsakade 
av en förträngning i halspulsådern (karotisstenos). 
 
Åderförfettning (ateroskleros) i halskärl är ett relativt vanligt tillstånd hos äldre 
människor. Åderförfettning utvecklas över tid och gör pulsådern styvare, tjockare 
och blodströmmen blir smalare.  
Man uppskattar att 10 % av befolkningen över 80 år har karotisstenos. De flesta 
som har karotisstenos har inga besvär eller symtom. Ibland sker en förändring i 
placket som bidrar till att små fragment åker med blodflödet upp i hjärnan. Detta 
kan ge symtom i form av ensidig förlamning, talsvårigheter, plötslig blindhet. 
Antingen går symtomen över inom 24 timmar, och då kallas det transitorisk 
ischemisk attack, TIA, eller får man mer varaktiga symtom, stroke.  
Stora randomiserade studier har visat att kirurgisk behandling av karotisstenos 
minskar risken för återinsjuknande i stroke jämfört med endast medicinsk 
behandling. 
 
Den kirurgiska behandlingen av karotisstenos syftar till att minska risken för ny 
stroke. Rekommendationen är att behandla patienter med symptomgivande 
karotisstenos skyndsamt. Medicinsk behandling med acetylsalicylsyra och 
kolesterolsänkande skall startas omedelbart och utredning med ultraljud görs så 
snart som möjligt för att hitta de som har en förträngning på halspulsådern. Inom 
14 dagar bör operation av karotisstenos äga rum, för att förhindra så många nya 
strokes som möjligt. 
 
Att man skall operera inom 14 dagar är välstuderat, men däremot saknas bevis för 
när inom dessa 14 dagar som patienterna har mest nytta av operation. Det har 
också skett en utveckling de senaste åren vad gäller medicinsk behandling och 
risken för att återinsjukna i stroke efter ett symtom från en karotisstenos kan ha 
förändrats jämfört med de studier som tidigare har gjorts. 
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Studierna i denna avhandling avser; 
Att studera risken att återinsjukna i stroke hos patienter med en symptomgivande 
karotisstenos med dagens medicinska behandling. 
Att studera risken att drabbas av stroke eller död vid operation av karotisstenos 
avhängigt av när operationen äger rum i förhållande till tiden för symtom. 
 
Studie I är en nationell populationsstudie där risken vid akut kirurgi, inom 2 dagar 
från neurologisk varningshändelse, visar sig vara signifikant högre än om man 
opereras efter dag 2. 
 
Studie II är en populationsstudie från Västra Götalandsregionen där patienter med 
symptomgivande karotisstenos som har gjort ultraljudsundersökning av 
halskärlen studeras för att analysera risken för återinsjuknande i stroke. I denna 
studie är risken för ny stroke lägre än i de flesta äldre studier, vilket skulle kunna 
bero på en bättre medicinering. 
 
Studie III, är en planerad populationsstudie där vi jämför risken att opereras akut 
inom 48 timmar från neurologisk varningshändelse med operation dag 3-14. Här 
fann vi en signifikant ökad risk vid akut operation jämfört med den senare 
behandlade gruppen. 
 
Studie IV är en uppföljande studie av studie I som i en validerad population visar 
en hög risk vid akut kirurgi, dag 0 och 1, jämfört med patienter som opereras dag 
2 till 7 (15.8% jmf 5.4%, OR 3.31, 95 % CI 1.47 – 7.45). 
 
Sammanfattningsvis är tidig operation, inom 14 dagar säker med undantag för de 
första två dagarna. Man bör fortsatt vara försiktig med operation inom detta akuta 
tidsintervall men därefter finns ingen anledning att dröja ytterligare med 
operation. Lämpligen skulle riktlinjerna ändras för att påskynda operation. De 
första två dagarna bör ägnas åt den viktiga medicinska behandlingen och utredning 
inför kirurgi. Fler studier behövs för att ta reda på operationsrisk och risk för 
återinsjuknande i stroke med dagens medicinska behandling. 
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Abbreviations 
AHA  American Heart Association 
ABCD2 Scoring risk including; 
Age,Bloodpressure,Clinical manifestations,Duration,Diabetes 
ABCD3-I See ABCD2, Dual TIA and carotid Imaging added 
BMT  Best Medical Treatment 
CAR  Carotid Artery Risk score 
CCA  Common Carotid Artery 
CEA  Carotid EndArterectomy 
CI  Confidence Interval 
DAPT  Dual AntiPlatelet Therapy 
ECA  External Carotid Artery 
ECST  European Carotid Surgery Trial 
ICA  Internal Carotid Artery 
MRI  Magnetic Resonance Imaging 
NASCET  North American Symptomatic Carotid Endarterectomy Trial 
NIHSS  National Institutes of Health Stroke Scale 
NR  Neurological Recurrence 
OMT  Optimal Medical Treatment 
OR  Odds Ratio 
P-value  Level of significance 
Pts  Patients 
RCT  Randomized Clinical Trial 
SCS  Symptomatic Carotid Stenosis 
SD  Standard Deviation 
SIE  Stroke In Evolution 
Swedvasc SWEdish VASCular Registry 
TIA  Transient Ischemic Attack 
WHO  World Health Organization 
WINGA Western region INitiative to Gather information on 
Atherosclerosis 
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Introduction 
Carotid stenosis as a cause of stroke 
”A stroke is caused by the interruption of the blood supply to the brain, 
usually because a blood vessel bursts or is blocked by a clot. This cuts off 
the supply of oxygen and nutrients, causing damage to the brain tissue.”  
 
     (The definition of stroke by the World Health Organization.) 
 
Stroke is one of the most common causes of disability among adults 
worldwide and the second most common cause of death. Over the last 
years the incidence of ischemic stroke has decreased in high income 
countries while it increases in middle and low income countries during the 
same time.1 However, there is a shift in the incidence in relation to age, 
stroke is increasing in younger patients in high income countries.2 
Background 
Stroke is the comprehensive term for ischemic and hemorrhagic damage 
to brain tissue. In Sweden it is the most common cause of hospitalization. 
Nearly 22 000 patients were registered with stroke in the national stroke 
register, RiksStroke, in 2016 and further 10 000 patients were registered 
due to a transient ischemic attack (TIA).3 The etiology of stroke is in 
86% ischemic and the most common cause is a cardio-embolic event. 
Approximately 15% of ischemic strokes are due to lesions in the 
extracranial or major intracranial arteries.4,5 
  
Atherosclerosis is a multifocal disease, affecting predominately large and 
medium-sized arteries, particularly where there is branching, tortuosity or 
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confluence of vessels. Angiographic, pathological and ultrasonic studies 
shows that the most common extracranial sites for atheroma are the aortic 
arch, proximal subclavian arteries, carotid bifurcation, and the vertebral 
artery origin. If a plaque in the carotid bifurcation ruptures it may 
dislodge plaque fragment, or stimulate to formation of thrombosis with 
subsequent embolism, most frequently into the area of distribution of the 
middle cerebral artery (MCA).  
In a neuro-epidemiologic study from 2013 the specific extracranial 
internal carotid artery disease causes approximately 8% of the ischemic 
strokes.6 Population-based registries on incidence involve a number of 
problems, the most important being completeness of case ascertainment. 
Patients with mild stroke never seeking hospital and patients with fatal 
stroke may be missed. 
History of carotid endarterectomy 
In 1953, DeBakey performed the first successful thromboendarterectomy 
for cerebrovascular insufficiency caused by an atherosclerotic occlusion of 
the carotid artery. In 1975, he himself wrote a case report, a nineteen years 
follow up study. The patient was observed until his death from coronary 
occlusion 19 years after carotid endarterectomy. Throughout that time the 
restored circulation in the carotid arteries was maintained.7 
 
During the subsequent two decades the number of these procedures grew. 
Fifteen thousand CEAs were performed in the United States 1971, and this 
increased to 34000 in 1976.  With an increased number of CEAs 
performed, more complications with peri-operative strokes were noticed.8 
The fear of bringing more harm than good in these patients increased 
among the clinicians, which eventually led to two landmark RCTs; The 
North American Symptomatic Carotid Endarterectomy Trial (NASCET) 
and The European Carotid Surgery Trial (ECST).9,10 
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NASCET and ECST 
In ECST and NASCET almost 6000 patients in over 200 centers  were 
randomized, comparing best medical treatment alone and best medical 
treatment together with CEA. The main inclusion criteria was ipsilateral 
carotid territory symptoms within the preceding six months. Both trials 
showed that CEA conferred significant benefit in symptomatic patients 
with a 70% to 99% stenosis. Based on these two randomized trials for 
symptomatic carotid disease, there is consensus that patients with TIAs, 
ocular TIAs, or minor stroke with good recovery and with 70% or greater 
carotid stenosis will benefit from surgery with an absolute stroke risk 
reduction of 17% at 2 years (NASCET) or approximately 10% at 3 years 
(ECST).  
In NASCET patients with symptomatic moderate stenosis (50-69%) also 
will benefit from surgery. The European and North American methods to 
determine degree of stenosis differs and a 70% stenosis by the European 
method is equivalent to a 40% stenosis by the North American method. 
Thereby the ECST could not find any benefit for surgery for the moderate 
stenosis determined by the ECST-method (Fig.1).  
 
The conclusion in both studies was that carotid endarterectomy is of 
proven value in stroke prevention in selected symptomatic patients. The 
long-term benefits are linked to initial operative risk. In selecting patients 
for CEA surgeons must consider both perioperative risks and life 
expectancy span contra stroke risk. 
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Figure 1. Two different methods for calculating degree of stenosis. 
Imaging 
Ultrasound 
The appropriate diagnostic algorithm prior to CEA has changed over the 
past years. Angiography was initially considered the golden standard as 
preoperative investigation, and used in the NASCET and ECST studies. 
Today most patients are investigated with duplex ultrasound alone. The 
major issues that must be addressed are the accuracy of duplex in grading 
the severity of the stenosis.  
There are several studies showing that, in expert hands, duplex scanning 
was equivalent to calculation of the degree of stenosis on angiography. 
Evidence suggests that if an experienced duplex operator perform the 
investigation the duplex has a sensitivity and specificity of 90% in 
detecting a stenosis >70%.11 The duplex examination gives accurate 
information regarding degree of stenosis, the length of the lesion and 
characteristics of the plaque. 
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Several studies have analyzed the benefit of CEA stratified for the severity 
of the stenosis.  
In pooled data from NASCET, ECST and the Veteran Affairs (VA) 
studies, Rothwell et al showed the absolute risk reduction of stroke and 
death at five years in symptomatic patients undergoing CEA with 50-69% 
and 70-99% carotid stenosis. This was also dependent on time from 
randomization to CEA.  
The benefit conferred by surgery diminished rapidly as the interval 
between randomization and CEA increased, especially in patients with 50-
69% stenosis (NASCET).12 
Plaque morphology and biomarkers 
The vulnerability of the plaque has been the subject of many studies in 
order to find patients at high risk for recurrent stroke. A study based on 
data from ECST showed that angiographic plaque surface irregularity is 
associated with an increased risk of ipsilateral ischemic stroke.13  
This factor is therefore included in the CAR-risk score, which is derived 
from the ECST. Furthermore, an ulceration or intra-plaque hemorrhage is 
associated with an increased risk of recurrent stroke, but no other 
characteristics of the plaque have been identified to correlate to elevated 
risk.14  
Ultrasound is the first-line modality for carotid disease and identifications 
of plaque ulcerations, but MRI with high resolution is also valuable for 
evaluating plaque composition. 
  
There are several studies that analyze different biomarkers that may be 
associated with vulnerability of the plaque.15 None are validated to be used 
in every day clinical practice. 
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Risk Score 
In the last decade, scores have been established to estimate the stroke risk 
following a TIA. The ABCD2 and the ABCD3-I scores are regarded as the 
best validated ones.16-19 These scores have been suggested to select patients 
for an intensified treatment, and rely on the summation of points associated 
with clinical factors that are independently predictive of stroke risk (age, 
blood pressure, clinical manifestations, duration of symptoms and 
diabetes).20,21 The ABCD3-I includes imaging and dual TIAs within seven 
days in addition to the ABCD2-score. 
 
Another risk score, Carotid Artery Risk score (CAR), estimates the 5-year 
ipsilateral stroke rates in a recently symptomatic patient with carotid 
stenosis of 50% or more treated with a modern optimized medical therapy 
(OMT). This scoring system has not been validated and is therefore 
regarded as provisional until the ECST-2 study has been completed. The 
CAR score includes age, gender, degree of stenosis, time from event to 
treatment, most severe ipsilateral event, previous myocardial infarction 
(MI), peripheral vascular disease, diabetes, hypertension and whether the 
plaque is ulcerated or not. 
Treatment of symptomatic carotid stenosis 
There are two important strategies for treating patients with symptomatic 
carotid stenosis, medically and surgically. The most important is probably 
the medical treatment, which has changed considerably over the past 
decades. 
Medical treatment 
Patients with symptomatic carotid stenosis should be informed about risk 
factor control. They should be advised stop smoking and offered smoking 
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cessation interventions. Exercise and avoiding obesity should be advised. 
In a meta-analysis, moderate or high levels of physical activity were 
associated with 25% relative risk reduction in ischemic stroke.22 Further, 
obesity is shown to increase risk of stroke prevalence, RRI 1.64 (95% CI 
1.36 – 1.99).23 
 
Antihypertensive treatment is recommended for patients with hypertension 
and asymptomatic extracranial carotid disease, to maintain a blood 
pressure below 140/90mmHg.24,25 In recently symptomatic patients with 
severe bilateral stenosis, aggressive antihypertensive treatment may not be 
advisable. However, a systolic blood pressure >180mmHg is an 
independent predictor for stroke after CEA. The recommendation is to 
reduce the blood pressure <180mmHg before surgical treatment. The 
evidence of benefit of a specific target blood pressure has not been 
established in the relation to the risk of exacerbating cerebral ischemia.26,27 
 
Treatment with statin is recommended prior to intervention in all patients 
undergoing CEA to reduce 30-day incidence of death and stroke.28-30 
Merwick et al showed a reduction of stroke in patients with acute 
symptomatic carotid stenosis treated with statins.31 
Regarding antithrombotic therapy, antiplatelet is recommended before oral 
anticoagulant as first choice treatment of extracranial carotid disease for 
prevention of cardio- and cerebro-vascular events. Aspirin alone or 
combinations with dipyramidole, or clopidogrel alone are the first choice 
treatment in AHA guidelines.32-37 Several studies have shown a benefit 
with dual antiplatelets (DAPT), aspirin and clopidogrel to prevent 
recurrent stroke in symptomatic carotid stenosis awaiting 
revascularization.21,35,38,39  
Batchelder et al showed a significant reduction in recurrent neurological 
events and spontaneous embolization prior to CEA without a significant 
increase in perioperative bleeding complications.40 However, there is a 
reason for caution since some studies shows a higher risk of hemorrhage 
performing CEA with dual antiplatelet therapy.41 
                                                 Optimal Timing of Surgical Treatment 
   
22…,,,. 
Surgical treatment 
In a meta-analysis, including more than 6000 patients, randomized within 
ECST, NASCET and VA the benefit of intervention within 14 days (from 
most recent event to randomization) was shown.42,43 Carotid 
revascularization in symptomatic carotid stenosis is, after these results, 
recommended in patients at low or average surgical risk who has had a 
non-disabling ischemic stroke, transient ischemic cerebral event with 
hemispheric symptoms or ocular TIA within the last 6 months.37,44 The 
perioperative stroke and/or mortality risk should not exceed 6%.42,43 
 
There are several techniques for carotid revascularization. The two 
standard interventions are carotid endarterectomy (CEA) and carotid artery 
stenting (CAS). There are no studies showing the advantage for CAS in 
the acute period of symptomatic carotid disease, and therefore CAS will 
not be discussed in this thesis. CEA can be performed as a conventional 
endarterectomy or eversion endarterectomy.  
There are different advantages and disadvantages with both methods. No 
randomized trials comparing the two techniques have shown any 
differences in morbidity or mortality, or rates of restenosis.45,46 
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Figure 2. Carotid endarterectomy with use of shunt and patch. 
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Timing of carotid endarterectomy 
The optimal timing for CEA after TIA or stroke remains an important 
and controversial issue. The risk of recurrent stroke should be balanced to 
the procedural risk. Most guidelines recommend that CEA should be 
performed within 14 days of symptom onset.37,44,47  
In the UK, the National strategy for stroke has adopted an even more 
aggressive approach and has recommended that symptomatic patients 
should undergo CEA within 48h of symptom onset.48 There is relatively 
little evidence supporting the 48h threshold in literature.  
Definitions in literature 
The different definitions of the neurological recurrent events (first event, 
index event, alarm symptom, referral event) complicate comparison, when 
trying to summarize the results from studies. The definition of a recurrent 
event based on first neurological event will overestimate the risk of 
recurrence then there is a population with “first neurological event” that 
never will be known to the health care system.  
Different studies are answering different questions. There is a disparity 
between studies that analyze the risk of recurrent stroke in patients not 
eligible for CEA and/or before known to the healthcare system, and studies 
that analyze the risk awaiting revascularization and/or recurrent stroke 
after the index event. Some studies also summarize the total risk of 
neurological recurrence, TIAs and stroke altogether. 
 
Regarding procedural risk, most studies present the results as risk of CEA 
stratified from most recent event. These results must be identified 
separately from the procedural risk stratified from the index event, which 
would possibly yield a different outcome. 
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Risk of recurrent stroke 
There is definite evidence that the highest risk period for stroke, after 
suffering a transient ischemic attack, is the first two weeks, and especially 
the first few days. Natural history studies of neurological recurrence have 
been reported but with changing of medical treatment regimen the past 
decades the risk of recurrence is presumably altered as well.49  
It is important to evaluate the risk in relation to best medical treatment 
given and also the individual risk for each patient. Contemporary natural 
history studies report that the incidence of recurrent ischemic stroke after 
an index TIA ranges from 2 to 8% at 48 hours, 4 to 17% at 72 hours, 8 to 
22% at 7 days and 11 to 25% at 14 days.50-53 Studies with highest risk of 
recurrent stroke includes stroke in evolution (SIE), probably not caused by 
a new embolization. 
Procedural risk 
The early high risk of recurrent stroke led to the recommendations to 
intervene early. Acute best medical treatment and CEA within 14 days of 
index event was recommended in most guidelines last decade.42 Data 
suggested that the procedural risk changed dependent on the timing of 
CEA with highest risk close to the index event.  
There were no studies on the peri-operative risk in the hyperacute time 
period after index event (0 to 2 days) and, today, there are still few studies 
reporting risk after CEA, stratified for delay, and only a minority of the 
patients in the studies underwent CEA within 48 hours.  
Different results partly due to different definitions of index event are 
presented. Most studies shows the risk of CEA in relation to time from 
most recent event and other studies presents the perioperative risk in 
relation to index event (defined as the event that led the patient to medical 
attention). Existing studies show that CEA could be performed day 3 to 14 
with a low procedural risk, but there is very limited information on 
procedural risk day 0 to 2.54-56 
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Changes over time 
The three landmarks RCTs regarding carotid endarterectomy (NASCET, 
ECST and VA) have been a great source of knowledge, and have been used 
in several sub-analysis over time.9,10,57 However, there are some problems 
associated with use of data from populations randomized more than 20 
years ago. The study design in these three trials are similar, but there are 
some differences in methodology.  
Veterans Affairs included only men, and the time after last neurological 
event to randomization had to be less than four months. In NASCET and 
ECST both genders were included and the elapsed time from last event to 
randomization had to be less than six months. Surgery, if assigned, should 
be performed at the earliest opportunity after randomization. The median 
time from randomization to trial surgery was 6 days.43  
The best medical treatment at time of inclusion was, 1300mg/day aspirin 
in NASCET, 325mg/day in VA, and was unspecified in ECST. 
 
Uncertainty, when studying procedural risk stratified for delay and optimal 
timing of surgical treatment with those data are obvious. The pooled data 
from the landmark RCTs, are analyzing procedural risk stratified for delay 
from most recent event to randomization and not from index event to 
CEA.43 
Furthermore, the advances in medical treatment the last decade raise the 
issue if the results from older studies are relevant today. 
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Aims 
The overall aim of this thesis was to investigate optimal timing of surgical 
treatment in patients with symptomatic carotid stenosis. 
 
 
Specific aims; 
 
To assess the early risk of recurrent stroke in symptomatic carotid artery 
stenosis (study II). 
 
To evaluate the procedural risk in symptomatic carotid stenosis when CEA 
is performed within two days from the index event (study I, III and IV). 
 
To evaluate if other procedural risk factors explain or contribute to the 
observed increase in risk when performing urgent CEA (study I, III, IV). 
 
To evaluate changes over time in risk of recurrent stroke and procedural 
risk. 
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Patients and Methods  
Study Design 
The study design of the four papers is summarized in Table 1. There are 
three register based studies and one study with consecutive patients from 
the region. Study I, III and IV are analyzing the procedural risk and study 
II is studying the risk of recurrent stroke in patients with symptomatic 
carotid stenosis. 
 
 
 
Table 1. Study design of the four studies in the thesis. 
 
 Design Patients Source Primary endpoint 
Study I 
Prospective 
national 
cohort study 
n 2596 Swedvasc 
30-days 
Stroke/Death 
after CEA 
Study II Retrospective cohort study n 397 WINGA 
30-days 
Stroke/Death 
in SCS-
patients 
Study III 
Prospective 
controlled 
study 
n 418 
Consecutive 
regional 
hospital data 
30-days 
Stroke/Death 
after CEA 
Study IV 
Matched 
cohort study 
Prospective 
national 
cohort study 
n 561 
n 4978 
Medical 
records  
and 
Swedvasc 
30-days 
Stroke/Death 
after CEA 
*SCS=symptomatic Carotid Stenosis 
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Swedvasc (Study I and IV) 
The Swedish registry for vascular surgery was created in 1987, and was 
nationwide by 1994. All centers performing carotid endarterectomy are 
registering in the web-based registry. Preoperative data as co-morbidities 
and demographics are recorded along with procedural data. Thirty day 
follow-up data includes morbidity, complications and outcome. In May 
2008 an updated version of the registry was launched, including alarm 
symptom, most recent event and time to intervention.  
The registry is linked to the Swedish National Population Registry, and the 
mortality data is therefore 100% accurate. External validation of the 
Swedvasc registry was performed 2000-2004 with an external validity 
regarding the carotid procedures of 93.4%.58 An even more recent 
validation of the carotid procedures, 2012, showed an external validity of 
98.8%. The internal validity in this study was estimated to 97.4%.59 
WINGA (Study II) 
“Western region INitiative to Gather information on Atherosclerosis” is a 
registry, which hold information on the clinical results of all carotid 
ultrasound examinations performed at Sahlgrenska University Hospital 
from January, 2004 until 2012. Sahlgrenska University Hospital is the sole 
supplier of vascular ultrasound diagnostics in the Gothenburg region with 
approximately 650,000 inhabitants.  
Ultrasound is the recommended first line investigation of carotid arteries 
after TIA and minor stroke according to strict local guidelines. The registry 
thus included all patients in this geographical area, who were referred for 
evaluation of carotid atherosclerotic disease. 
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Definitions 
In study I, III and IV we used the definitions from Swedvasc; 
 
Alarm symptom / Index event / Referring event and Qualifying event: is the 
neurological ischemic symptom that brought the patient to hospital, except 
in paper III, there qualifying event is defined as most recent event. 
 
Most recent event: is defined as last ischemic symptom preceding CEA. 
 
Diabetes Mellitus: is defined as diabetes treated with oral antidiabetics and 
/ or insulin. 
 
Hypertension: if on antihypertensive medication. 
 
Heart risk: is answered with yes if patient suffers heart failure, angina 
pectoris, earlier MI. 
 
Amaurosis fugax / ocular TIA / ocular stroke: cannot be differentiated and 
is registered as the same type of index event. 
 
TIA: neurological deficit lasting < 24 hours. 
 
Crescendo TIA: daily ischemic events immediately before CEA, including 
progressive stroke and stroke in evolution. 
 
Minor stroke: is defined as neurological symptoms lasting more than 24 
hours, but less than one week, or minor disabilities. 
 
Major stroke: major disabilities lasting more than 24 hours. 
 
Stroke in evolution: continuously worsening or fluctuating symptoms 
(included in crescendo TIA in Swedvasc). 
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Stroke within 30 days is registered as minor or major stroke and 
categorized as ipsilateral, contralateral, hemorrhagic, ischemic and/or 
vertebrobasilaris-territory. 
 
In study IV, the definitions crude and validated Swedvasc data are used. 
Crude Swedvasc data are data that are collected from the registry without 
cross-checking in medical records. All data referred as validated data are 
brought from medical records at the local hospital. 
Ethical approval 
The Gothenburg Regional Ethical Review Board approved the protocols. 
In Study III, written informed consent was obtained from all participants. 
In all other studies registry data was used as approved by the Ethical review 
board. 
Patients and primary endpoints 
Study I 
Hypothesis: There is no increased procedural risk of CEA for symptomatic 
carotid stenosis in relation to time from index event. - studied in a national 
population-based registry cohort. 
 
Data for patients who underwent intervention for symptomatic carotid 
stenosis in Sweden, between May 12, 2008, and May 31, 2011, were 
obtained from Swedvasc. Patients registered as receiving stenting, ligature, 
bypass, exploration or transposition were excluded. Three patients were 
excluded due to missing follow up at 30 days.  
All data regarding co-morbidities, demographics, procedural risk and time 
from index event to CEA were collected from the registry. Procedural 
adverse events were defined as minor stroke, major stroke or death. 
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The study population (n=2596) was divided into four subgroups depending 
on time to intervention: 0 to 2 days (n=148), 3 to 7 days (n=804), 8 to 14 
days (n=677) and 15 to 180 days (n=967). Complication rate was then 
stratified for all four subgroups. 
 
The primary endpoint was stroke and/or death within 30 days of CEA. A 
multivariable analysis was also performed to identify independent risk 
factors for CEA. 
Study II 
Hypothesis: The early risk of recurrent stroke in patients with symptomatic 
carotid stenosis is as high as earlier studies have described. 
 
All patients with carotid examination, 2004 to 2006 and 2010 to 2012, 
from the WINGA registry were collected. Patients in the registry with 
significant carotid stenosis, defined as NASCET ≥50%, were analyzed. 
The medical record of each patient was searched manually.  
Patients with symptomatic carotid stenosis ≥50% (NASCET) were 
included, while patients with lower grade stenosis, asymptomatic stenosis 
or occlusion were excluded. Major stroke and stroke-in evolution (SIE) as 
index event were exclusion criteria. Time and type of index event, time to 
ultrasound from referral event and time to CEA or primary endpoint were 
monitored. The patients were censored at time of CEA, recurrent 
stroke/death or 30-days follow-up.  
 
Primary endpoint was recurrent stroke, defined as ipsilateral ischemic 
event lasting more than 24 hours or being fatal. Patients with minor stroke 
as index event were considering having a recurrent stroke if clinical 
worsening of symptoms were clearly described. NIHSS-score was 
available from 2010.  In the cohort 2004 to 2006 the worsening of 
symptoms was approximated before and after recurrent event through the 
medical records (differs from the description in published paper, errata is 
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sent to the editor of EJVES). Recurrent TIAs were not included as 
endpoint. 
 
Two different cohorts depending on referral time were chosen, 2004 to 
2006 and 2010 to 2012. The purpose was to analyze two cohorts with 
different clinical properties. In the earlier cohort there was longer delay 
between referral event, ultrasound and CEA, having the opportunity to 
longer follow-up but missing some patients with major strokes before 
ultrasound has been performed.  
The later cohort, 2010 to 2012, has the advantage that ultrasound 
investigation was performed with short delay from referral event, but the 
follow-up time was limited due to a shorter delay to CEA. The medical 
treatment was also a factor that had changed in between the two periods, 
and could be important for the results. 
Study III 
Hypothesis: CEA within 48 hours would not increase, or only slightly 
increase, the risk of per- or postoperative complications versus CEA 
performed during the later period (day 2 to 14). 
 
The Carotid Alarm Study, was a population-based, prospective study of 
consecutive patients undergoing CEA within 14 days of symptomatic 
carotid stenosis. Patients were included from October, 2010 to December, 
2015 at two centers in the region. Procedural risk was analyzed in patients 
having CEA within 48 hours and compared with those operated on 
between 48 hours and 14 days after an ipsilateral ischemic event. Patients 
with major stroke, NIHSS >5 or infarction >3cm on diffusion weighted 
magnetic resonance imaging (MRI) were excluded, as well as patients with 
SIE, severe life-limiting disease and intravenous thrombolysis due to the 
ischemic event. 
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The primary endpoint was the composite of death and/or any stroke within 
30 days of CEA. Secondary outcomes were any stroke, ipsilateral stroke 
or ischemic ipsilateral stroke within 30 days of surgery.  
Study IV 
Hypothesis: There is no increased procedural risk of CEA for symptomatic 
carotid stenosis in relation to time from index event. - studied in a 
validated population based cohort. 
 
In study IV, we obtained data on all patients in the register from May 12, 
2008 until October 31, 2014 who had carotid endarterectomy (CEA) within 
two days from alarm symptom (n=343) They were matched 1:1 to a cohort 
that was registered to have undergone CEA day 3 to 7 from alarm 
symptom. Two factors, already known to influence timing of CEA, were 
used for matching, type of index event and which part of the week the 
patient was presented to health care.  
Validation of the parameters in the Swedvasc registry was performed using 
individual´s medical records. Due to a high proportion of misclassification 
the matching was abandoned and all patients with validated data and CEA 
within 7 days from index event were used in further analysis. Procedural 
risk stratified for delay was analyzed. The patients were also split into two 
cohorts depending on which year CEA was performed, 2008-2011 and 
2012-2014, to investigate the change over time. 
 
We also obtained data for all patients who underwent intervention for 
symptomatic carotid stenosis in Sweden between May 12, 2008 and 
October 31, 2014, and were reported in SWEDVASC (n=4978). Analysis 
regarding time from index event to CEA and procedural risk was made. 
The patients were subdivided as in earlier study, 0-2 days (n=352), 3-7 
days (n=1906), 8-14 days (n=1302) and 15-180 days (n=1418). We also 
split the patients into two groups regarding which time period they were 
treated, (2008-2011, n=3086) and (2012-2014, n=1892). A multivariate 
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analysis investigating the peri-operative risk per day 0, 1 and 2 
separately, with day 3 as reference, was made. 
Primary endpoints in both part I and II of the study were all cause mortality 
and stroke within 30 days of surgery. 
Statistical methods 
Statistical analyses were performed using the IBM SPSS version 18.0-23.0 
(SPSS Inc., Chicago, IL, USA). Categorical variables were compared 
using χ² test significance analysis or when appropriate in smaller numbers 
two-sided Fisher exact test. Continuous variables were compared using 
analysis of variance and expressed as mean with standard deviation. Odds 
ratio (OR) has been used to compare two groups and expressed as OR with 
95% confidence interval and p value. 
 
In Study II the SAS system version 9 was used for Kaplan-Meier curves. 
Analysis with log-rank test was performed. Confidence intervals were 
expressed, as was number of patients at risk by different time points, to 
clearly show censored cases. 
In study III, odds ratios and 95% confidence intervals (CI) for the primary 
and secondary endpoints were calculated using logistic regression 
analysis. For the primary endpoint, variables with a p value < 0.1 in the 
univariate analyses were included in a multivariate model. 
In study I, III and IV, multivariate associations were assessed by a logistic 
regression analysis and results are presented as ORs with confidence 
intervals (95%). Significance was assumed as p<0.05.
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Results 
Summarized results 
The results from all four studies in this thesis are summarized in Table 2. 
These results indicate an increased procedural risk with urgent CEA, which 
seems to outweigh the risk of early recurrent stroke in patients with 
symptomatic carotid stenosis. Comparing the results regarding recurrent 
stroke with procedural risk when 48 hours from index event have elapsed, 
CEA is favorable compared to non-surgical management.  
There are several limitations with this comparison. Some patients are 
included in more than one of the studies, and some of the results in the 
table are extracted from the study results even though it was not the 
primary endpoint. 
Study I 
The overall stroke and mortality rate in 2596 Swedvasc-registered CEAs 
performed between May, 2008 and May, 2011, was 4.8%. There was no 
significant increased risk if CEA was performed within 14 days compared 
to surgery two weeks after the index event (4.5% vs 5.4%).  
When the population was subdivided according to time to intervention 
from index event the stroke/death risk of urgent CEA, within 2 days, was 
significantly higher, 11.5% (Fig 3). Only 5.7% (148/2596) of the 
population had undergone surgery within 2 days from the index event. 
 
In order to investigate if a fast track strategy applied in some vascular 
surgery units was associated with different surgical risk, five centers with 
a very high percentage of urgent CEAs were identified. The mortality and 
stroke rate for CEA performed within 2 days, at these centers, did not differ  
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compared to centers with longer time between index event and intervention 
(11.3% vs 11.6%). 
 
In a multivariate analysis female gender, diabetes, use of shunt and urgent 
CEA were considered independent predictors of increased risk. Urgent 
CEA had OR 4.24 (95% CI 2.1 – 8.7, p<0.001) for peri-operative 
complications compared to patients in the reference group who had surgery 
day three to seven. 
 
 
 
 
 
 
Figure 3. Risk of 30-day stroke/death after CEA depending on time to 
intervention. Risk is in per cent and time is presented in days from index 
event. Data from Study I. 
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Study II 
The risk of recurrent stroke within 30 days after an index event, was 7.5% 
(95% CI 4.4 – 10.6), in patients with symptomatic carotid stenosis 
(n=397). Within two days 2% (95% CI 0.6 – 4.4) of the patients had 
suffered a recurrent stroke and after one week the risk was 4% (95% CI 
2.0 – 5.9). Patients with minor stroke (n=182) as referring event had a 
significantly increased risk of recurrent stroke compared to patients with 
TIA (n=145) (Fig 4). No patients with ocular TIA had a recurrent stroke.  
Comparing the early cohort (2004-2006, n=194) with the latter (2010-
2012, n=203) the frequency of recurrent stroke did not differed 
significantly (2004-2006; 14/194 (7.2%) 2010-2012; 9/203 (4.4%),  
p 0.235). 
 
 
 
 
 
Figure 4. Risk of recurrent stroke at day 2, 7 and 30, from the index event 
presented in per cent. Dark grey bars presents TIA patients, and light grey 
bars are patients with minor stroke. 
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A minor group of patients (n=75) had performed ultrasound within 1 day 
after index event, with low risk of selection bias. No recurrent strokes had 
occurred day 2 in this group, however by day seven 4.1% (95% CI 0 – 9.6) 
had recurred, and by day 30, 9.0% (95% CI 0 – 18.9). 
 
Data regarding medical treatment were missing in many cases due to 
difficulties in retrieving data from medical records. In the earlier cohort, 
147/194 (76%) had data about statins and antiplatelets and in the 2010-
2012 cohort data was accessible for 170 of 203 patients (84%). Patients 
treated with statins when discharged from the hospital, increased from 53% 
to 97% between these time periods, and at the same time, the use of 
clopidogrel rose from 4% to 36%. 
Study III 
A total of 418 consecutive patients were included in the Carotid Alarm 
Study. The overall 30-day mortality and stroke risk was 3.8%. Out of the 
418 patients 75 had CEA within 48 hours from most recent neurological 
event, and 46 were operated within 48 hours from the referring event. 
Patients undergoing CEA within 48 hours after most recent event had a 
significantly increased risk for stroke and/or death as compared to patients 
undergoing surgery 48 hours to 14 days after qualifying event; 8.0% versus 
2.9% (OR 2.90 95% CI 1.02 – 8.23; p 0.049). For the 46 patients who had 
surgery within 48 hours from referring event the combined mortality and 
stroke rate was 10.9%. 
 
In a logistic regression analysis use of shunt, CEA performed out of office 
hours and CEA within 48 hours after qualifying event were all 
independently associated with a significantly increased risk of stroke 
and/or death (use of shunt: OR 4.02 95% CI 1.36 – 11.93; p 0.012, CEA 
out of office hours:  OR 3.65 95% CI 1.14 – 11.67; p 0.029, CEA<48 h 
from most recent event: OR 3.07 95% CI 1.04 – 9.09; p 0.042). 
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Study IV 
Validated Data 
In study IV, 686 patients, identified in the Swedvasc registry, were 
validated through medical records. After validation 561 patients remained 
for analysis. Twenty-one were excluded due to missing follow-up and 104 
patients were misclassified in the Swedvasc registry and had CEA > 7 days 
after the index event. In this cohort with validated data the overall mortality 
and stroke rate was 6.4%. Analyzing the procedural risk per day showed a 
high risk day 0 and 1. Only 57 patients (10%) had surgery within 1 day. 
When stroke and death rate was compared, between CEA day 0 to 1 and 
CEA day 2 to 7, there was a significantly increased risk in the group treated 
urgently (15.8% day 0 to 1 versus 5.4% day 2 to 7, p 0.002, (OR 3.31, 95% 
CI 1.47 – 7.45)). 
 
The procedure risk in the two time periods 2008-2011 and 2012-2014 were 
analyzed and showed 8.2% (24/293) risk of stroke/death in the earlier 
cohort compared to 4.4% (12/268) in the latter cohort (p 0.07). Analysis 
regarding medical treatment showed a significant increased use of 
clopidogrel, dual antiplatelet and statins comparing 2008-2011 with 2012-
2014 (clopidogrel; 26.6% vs 44.8%, p<0.001, statins; 74.1% vs 86.6%, 
p<0.001 and dual antiplatelet; 21.5% vs 33.6%, p<0.001). 
Crude Swedvasc Data 
The overall stroke and mortality rate in the 4978 patients with symptomatic 
carotid stenosis and CEA from Swedvasc was 3.7%. There was a 
significant increased procedural risk when CEA was performed day 0 to 2 
after the index event (7.7%) compared to day 3 to 7 (2.9%), day 8 to 14 
(3.3%) and day 15 to 180 (4.1%). The same analysis as in the validated 
data comparing day 0 and 1 with 2 to 7, shows significant increased 
risk with urgent CEA (day 0 to 1; 11.0% (12/109), day 2 to 7; 3.3% 
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(70/2149), p<0.001, OR 3.4; 95% CI 2.8 – 4.0). 
The procedural risk per day, 0 to 3, was analyzed in a multivariate 
analysis, where day 3 was day of reference. The results showed a 4-fold 
increased risk for CEA day 0 and 3-fold risk day 1, compared to day 3. In 
Figure 5, the procedural risk per day (0 to 7) is presented. 
Comparing results from the cohort treated 2008-2011 with the cohort 
treated 2012-2014 showed a reduction in the risk of mortality and stroke 
after CEA (2008-2011; 4.5% (139/3086) versus 2012-2014; 2.3% 
(44/1892), p<0.001). Furthermore, in the cohort 2010-2012, only major 
stroke as complication differed significantly between the urgently treated 
group (0 to 2 days) and the other groups (3 to 7 days, 8 to 14 days and 15-
180 days). 
 
 
 
 
 
Figure 5. Peri-operative risk exposed in per cent per day, Swedvasc 
crude data, 2008 to 2014. 
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Discussion 
General discussion 
There is convincing evidence that CEA confers maximum benefit if 
performed within 14 days after the index event. The optimal timing within 
these 14 days is, however still a controversial issue. The aim of the studies 
presented in this thesis is to provide further knowledge, in order to 
determine the optimal timing for surgical treatment. 
Natural history of symptomatic carotid stenosis 
In study II early risk of recurrent ipsilateral stroke from index event in 
symptomatic carotid stenosis was shown in a population-based cohort. The 
risk of recurrent ipsilateral ischemic stroke turned to be lower than earlier 
studies had shown, 2% by day 2, 4% by day 7 and 7.5% by day 30 (n=397). 
The early risk of recurrent stroke after an index event is the rationale to 
perform CEA as soon as possible, and at least within 14 days. The risk of 
definitive stroke in patients with symptomatic carotid stenosis has to be 
balanced against the risk of CEA stratified for delay. There is a 
heterogeneity among studies reporting risk of stroke in patients with 
symptomatic carotid stenosis. The reasons for these diverse results are 
manifold, but some of the central definitions that needs to be addressed 
are; 
 
1. Definition of recurrent stroke. From which event is the recurrent stroke 
defined? From an event that brought the patient to medical care or from a 
prior event that the patient never choose to seek medical attention for? Or 
from a recurrent event that occurred in hospital after admission? 
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2. Event definition used as inclusion criteria. Which index event 
constituted the inclusion criterion for each study? Is stroke-in-evolution 
included? Is ocular TIA included? Are the results reported separately due 
to type of symptoms at presentation? 
 
3. Timing of inclusion. At what time, in relation to index event, are the 
patients included? 
 
4. Local tradition. Which medical treatment was considered to be best 
practice at the time of inclusion? Is this reported separately? 
 
5. Eligibility. Are only patients eligible for CEA included and if so, what 
is the definition of eligibility for CEA? 
 
6. Censoring at follow up. Studies censored by CEA or CAS will probably 
show a lower risk of stroke depending on when surgery is performed.  
 
An overview of different criteria used in recent studies are presented in 
Table 3. 
 
The current guidelines recommend CEA, within 14 days or as soon as 
possible after the neurological event. Our results are in accordance with 
those guidelines, even if study II and some more recent studies show a 
lower risk of recurrent stroke than other studies. In our opinion, the 14 days 
threshold should be brought forward in order to prevent more strokes in 
patients with symptomatic carotid stenosis. The medical treatment in the 
acute period after index event seems to be of major importance for 
prevention of recurrent stroke in patients awaiting CEA and should be 
instituted as soon as possible.40,60,61 
 
Ocular TIA, as index event, seems to indicate a lower risk of recurrent 
stroke compared to TIA and minor stroke. 38,52,62   
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Procedural risk of CEA stratified for delay 
Three studies in this thesis have investigated and discussed the risk of very 
urgent carotid endarterectomy. All three of them (I, III and IV), show 
similar results with a significant increased procedural risk the first days 
after index event. 
 
The pooled analysis of NASCET and ECST trials showed a time-
dependent benefit of CEA, and the recommendation for revascularization 
changed from the 4 to 6 weeks delay to a more urgent procedure, within 
14 days.42 However, this pooled analysis was not designed to address the 
very early timing of CEA in detail and only stable patients were included. 
Medical therapy for stroke prevention has improved since these original 
trials, with an increase in use of statins, more active antihypertensive 
treatment and a more active antiplatelet regimen. Not only the procedural 
risk declines with more aggressive medical treatment, but also the risk of 
recurrent stroke.35,38-40,60 
  
Furthermore, peri-operative stroke as well as stroke in patients awaiting 
CEA are of similar severity.26 Several studies have reported on procedural 
risk attributable to early CEA after the pooled analysis of endarterectomy 
RCTs (NASCET, ECST, VA). There is indisputable evidence that CEA 
within 14 days from index event is associated with decreased morbidity 
and mortality compared to medical treatment alone.65,66 Within the time 
frame of two days between index event and CEA there are conflicting 
results on procedural risk, with small individual studies and lack of 
standardized definitions for urgent CEA.  
DeRango et al concluded that urgent CEA within 2 days from index TIA 
is relatively safe, with a peri-procedural stroke risk of 2.7%. Stroke as 
index event was associated with a surgical risk as high as 8%.67 
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There are some larger national audits to report on outcomes, stratified for 
delays to CEA; 
 
1. Study I in this thesis, reported a significantly increased risk if surgery 
was performed within 2 days from index event. Only 5.7% of patients were 
urgently treated (148/2596), but the risk of stroke/death for this small 
fraction was as high as 11.5% at 30 days.68 
 
2. Loftus et al, presented the results from the UK National Vascular 
registry, in which 3.4% of the cohort (n=780) had CEA within 48 hours, 
also defined from index event.69 The risk for stroke/death was 3.7% in this 
national audit, which was significantly higher compared to CEA after 48 
hours (2.0%, day 3 to 7) 
 
3. An Austrian audit showed that 27% of the patients (206/761) had CEA 
within 2 days of most recent event.54 The stroke/death rate was 4.4% and 
was not significantly increased compared to CEA after more than two 
days. 
 
4. A recent German audit, also presented procedural risk within 2 days 
after most recent event, using the same definition as in the Austrian audit.56 
The mortality and/or stroke rate was 3.0% with 9.2% of the population 
having urgent CEA (5198/56279). 
 
5. Study IV (crude data) in this thesis, with partly the same population as 
in study I, showed that 7.1% of the patients had CEA within 2 days from 
index event (352/4978), and the procedural risk was 7.7% in this group. 
 
6. In addition, there is also a recent register based study from the Vascular 
Study Group of New England with 9.7% CEAs performed within 48 hours 
from index stroke (96/989). This study showed a 7.3% risk of procedural 
complication in the urgent treated group, which was significantly increased 
compared to if CEA was performed day 2 to 5 (4.0%).70 
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Notably, the Austrian or German studies have not reported risk stratified 
for delay after index event. In study IV of the thesis, the daily risk was 
presented and the procedural risk day zero and one after index event was 
higher than the thresholds for acceptable risk in guidelines. To summarize 
the results of these studies, accumulating evidence clearly suggest that the 
procedural risk the first couple of days are higher than in the later phase. 
 
Studies analyzing the procedural risk stratified for delay from the most 
recent event do not show any increased risk when performing CEA within 
48 hours. The only exception from this is study III in this thesis. A 
summary of studies analyzing risk of acute CEA is presented in Table 4. 
The different definitions of urgency as well as outcome are presented. 
Studies reporting time from the most recent event generally show a lower 
procedural risk than studies with index event as starting point. 
Merging the results from the different groups presented in table 3, the 
procedural risk of urgent CEA from most recent event is 3.1% versus 4.9% 
for CEA within 48 hours from the index event. 
 
The procedural risk in patients with ocular TIA as index event is reported 
low, as is the risk of recurrent stroke for these patients. Furthermore, 
analysis of the Society for Vascular Surgery Carotid Registry revealed that 
the risk of perioperative stroke with an index symptom of ocular TIA is no 
different from that of an asymptomatic patient.71 Patients with ocular TIA 
should be recommended the best medical treatment but not surgery, at least 
if the patient is at high risk factors for surgery. 
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Table 4. Comparing procedural risk within 48 hours or 2 days from index 
event or most recent event. 
 
Optimal timing of CEA 
The results from the studies regarding early recurrent stroke and 
procedural risk lead to the conclusion that CEA should be performed as 
soon as possible after the index event. However, we consider that surgery 
within the first 48 hours is an exception to this recommendation and should 
be avoided due to the increased procedural risk. In our opinion the higher 
risk of peri-operative complications in day 0-1 outweighs the risk of 
recurrent stroke in this phase. 
 Patients 
(n) 
Time for CEA from 
index event/most recent 
Stroke/Death 
n (%) 
Barbetta 2014 72 45 Index event 2 (4.4) 
Capoccia 2012 73 48 Index event 1 (2.1) 
Chisci 2015 74 30 Index event 3 (10.0) 
Mussa 2009 75 27 Index event 2 (7.4) 
Tvisgoulis 2014 76 20 Index event 2 (10.0) 
Strömberg 2012 68 148 Index event 17 (11.4) 
Strömberg 2015 62 15 Index event 3 (20.0) 
Strömberg (study 
IV-validated data) 
219 Index event 16 (7.3) 
Loftus 2016 69 780 Index event 29 (3.7) 
Averginos 2017 70 96 Index event 7 (7.3) 
Nordanstig 2017 77 75/46 Most recent/Index event 6 (8.0)/ 5 (10.9) 
Ferrero 2014 78 176 Most recent 7 (4.0) 
Gajin 2013 79 58 Most recent 0 (0.0) 
Rantner 2014 54 206 Most recent 9 (4.4) 
Sharpe 2013 55 41 Most recent 1 (2.4) 
Tsantilas 2016 56 5198 Most recent 156 (3.0) 
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There is no evidence of increased procedural risk day 3 to 7 compared to 
day 8 to 14, it may therefore be wise to consider changing guidelines to a 
more prompt revascularization strategy aiming at day 3 to 7. It may even 
be that CEA at day 2 after the index event yields a lower risk for peri-
operative complications than risk of recurrent stroke, and maybe this will 
be the optimal day to aim for. 
  
Considering the results from studies regarding recurrent risk and 
procedural risk, it is important to note that “high risk” for recurrent stroke 
is not the same as “high risk” for CEA. A high risk for a recurrent stroke 
in a patient waiting for surgery does not automatically imply a higher 
procedural risk. Therefore, the peri-procedural risk has to be carefully 
balanced to the risk of natural history of the disease.  
Changes over time 
The risk of recurrent stroke and risk of CEA both changes as optimal 
medical therapy and life style are changing. In study II, almost two thirds 
of the patients with recurrent stroke were from the earlier cohort, 2004-
2006, but there was no significant difference between the groups. In study 
IV the results from crude Swedvasc data showed a decreased procedural 
risk over recent years, comparing 2008-2011 (4.5%) with 2012-2014 
(2.3%). There are certainly many factors influencing changes of risk, but 
medical treatment is the only evident noticeable factor in the studies in this 
thesis. With an increased use of statins and dual antiplatelets the procedural 
risk seems to lower as the risk of recurrent stroke awaiting 
revascularization. Several recent studies support the importance of acute 
medical strategy.21,35,38-40,80 
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Methodological considerations – Limitations 
Selection Bias 
Study I, III and IV includes only symptomatic patients who eventually 
underwent CEA. Patients deemed to be at high surgical risk, and for other 
reasons were not offered CEA were not included. In study I and IV, a small 
percentage of patients undergoing CEA during this time period may not 
have been registered in Swedvasc. In study I and study IV (crude data) data 
have been reported wrong in some patients, the reason for doing a validated 
study from medical records (Study IV- validated data). Vascular surgeons 
are responsible for reporting 30-days follow-up in half of the cases in 
Swedvasc, the other part is managed by neurologists. There could be 
differences between the way neurologists and surgeons report adverse 
events.  
In study II, patients are included at time of ultrasound, missing some 
patients between referring event and investigation. Also, there is a possible 
bias due to many censored patients undergoing early CEA in the later time 
period. In Study III the selection of patients are not random. There is a 
potential risk that urgent CEA is performed in patients where the 
neurologist or vascular surgeon believes in the benefit, or vice versa. 
Another limitation with the Carotid Alarm Study is the low proportion of 
CEA performed within 48 hours. This could have influenced the results. 
Information bias 
Information bias could be a limitation in all studies based on registry data. 
Outcome after CEA that is reported by the vascular surgeon who 
performed the operation tends to be better than if follow-up is performed 
by someone without relation to the surgeon.81 
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Confounding 
In study I, III and IV (validated data) the confounders are presented in table 
one. The most important confounder in the mentioned studies is probably 
crescendo TIA as index event. The validated part in study IV is stratified 
for this confounder. The logistic regression analysis performed in study I, 
III and IV is an attempt to adjust for confounders. 
Power 
Most trials on procedural risks of urgent CEA suffers from limited power 
due to the low number of observations in the first few days after index 
event. Our studies are no exception and we therefore have limited 
possibilities to study procedural risks especially within the first 2 days 
from index event. 
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Conclusion 
Awareness of the procedural risks of urgent CEA was heightened after the 
publication of Swedvasc data (study I). Even if the message was clear, that 
CEA beyond two days from index event was not associated with increased 
procedural risk, other authors have argued that our article may be a further 
justification for deferring CEA.82 In this thesis, the conclusion regarding 
optimal timing of surgical treatment, is that acute CEA is safe, with the 
exception for day 0 and 1, and day 2 is uncertain. Patients will benefit from 
a more expedited strategy and it is time to change guidelines, and 
recommend CEA within 7 days from index event, with the exception for 
the first days after index event. 
 
Ocular TIA has a low risk of recurrent stroke and also a low perioperative 
risk. The benefit of CEA is not clearly evident in these patients, and further 
studies are needed. 
 
A more frequent use of dual antiplatelet treatment and statins over time 
may have altered the risk profile for both recurrent stroke and procedural 
risk. The impact of intense medical therapy on the optimal timing of CEA 
is unclear. More studies are needed to analyse the natural history of disease 
and also the risk of urgent CEA with optimal medical treatment. 
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Future Perspective 
There are still several areas of research in patients with symptomatic 
carotid disease, which can improve treatment and better answer the 
question who benefits most from surgery. 
 
The best way to study the optimal timing of surgical treatment in patients 
with symptomatic carotid stenosis is to study the combined risk of 
recurrent stroke and procedural risk. Inclusion of patients should be done 
at time of medical attention or at least within 24 hours from index event. 
Fast track strategy with ultrasound or CT angiography should enable 
immediate inclusion of patients with carotid stenosis after their index event 
to avoid selection bias. Randomisation between OMT and CEA day 0 to 1 
and OMT and CEA day 3 to 7 should be studied. Power calculation with 
power 0.80 and significance level p<0.05 and a possibility to identify a 4% 
difference in risk (10% vs 6%) would require 721 patients in each 
treatment arm. Approximately 800 CEAs for symptomatic carotid stenosis 
are registered each year in Swedvasc. If 40% is included nationwide each 
year, it would take approximately 4 years to meet the goal of inclusion. An 
international multi-centre study could be a possibility to further increase 
the inclusion rate. 
 
Today, we expose patients with no benefit at all to surgical risk. 
Development of more individualized risk factors for recurrent stroke 
would improve selection of patients for CEA. Imaging based on plaque 
morphology and plasma biomarkers for stratifying the risk are developing 
areas in research, however, much work is needed before they can be used 
in everyday clinic. 
                                                 Optimal Timing of Surgical Treatment 
   
55…,,,. 
Acknowledgements 
I would like to sincerely thank all people who have supported me through 
all the years it took to write this short thesis. 
 
Göran Bergström, my head supervisor, for providing challenging amount 
of red color in my manuscripts and for encouraging me to go on but without 
ever stressing me.  
 
Klas Österberg, my co-supervisor and head of the Department of Vascular 
Surgery at Sahlgrenska, for support and friendship. 
 
Johan Gelin, my co-supervisor, former head of the Department of Vascular 
Surgery and an excellent surgeon, for introducing me to vascular surgery 
and insisting that it is possible to have a large family and still be an 
awesome vascular surgeon.  
 
Lasse Karlström, surgeon/philosopher, for coming up with the idea to 
initiate study I, and for making the changes in the Swedvasc registry that 
made this thesis possible. 
 
All my colleagues at the Department of Vascular Surgery, for all the extra 
work you had to put in while I wrote my manuscripts and this thesis. 
 
And especially thanks to; 
Angelica, for being a fun and supportive colleague and room-mate, and for 
relieving me temporarily from the burden of scheduling during the writing 
period. 
Håkan, for being a very good friend and colleague no matter at what time 
of day or night help is needed. 
Marcus, for boosting my self-confidence. 
                                                 Optimal Timing of Surgical Treatment 
   
56…,,,. 
Joakim, for tips and tricks regarding research. 
Kristian, for being a responsible and jovial colleague. Thank you for your 
help with statistics. 
Urban, Norman, Lennart, Christer and Peter for helping me being the 
vascular surgeon I am today.  
 
Torun Österberg, for being an excellent statistician and friend. 
 
Swedvasc, all vascular surgeons in Sweden and the patients, for making 
this possible and Swedvasc for financial support and providing data. 
 
Rosie Perkins at Wallenberg lab, for your help with the linguistics in study 
I. 
 
The colleagues at Wallenberg lab, especially Marie-Louise, for your 
kindness every time I show up, although it is rare (unfortunately). And also 
for the great effort to start up the femoral express study, including cool 
official cars with stripes! 
 
IT-Sven, for the handling of my total lack of knowledge about computers. 
Always happy and always there when I call. 
 
Annika Nordanstig, first author of Study III, for great teamwork and many 
interesting discussions. 
 
Lars Rosengren, Monica Argus, Tony Lundh, Katarina Jood, Jan-Erik 
Karlsson and all other colleagues from the neurology clinic, for all your 
knowledge and the teamwork during study III. 
 
Ulf Hedin, for revising the construction of the thesis and preparing me for 
the 10th of November. 
 
Stella Funnemark, for your fantastic illustrations. You are truly gifted. 
                                                 Optimal Timing of Surgical Treatment 
   
57…,,,. 
Mesta av allt, tack till; 
 
Joakim, tack för att du är den du är, den bästa livskamrat man kan tänka 
sig. Jag är samtidigt glad att inte behöva tacka dig för att du har gjort allt 
under perioden av skrivande, utan att vi har levt som vanligt. Tack för 
hjälpen med alla språkliga spörsmål. 
 
Elin, Olle, Erik and Ellen, tack för att ni har stört mig flera gånger om 
dagen, så att jag inte har kunnat fly från det verkliga livet. Elin, tack för en 
fantastisk omslagsbild. Och slutligen Ellen som har gjort det möjligt. Utan 
föräldraledighet från kliniken, för att ta hand om dig, hade jag inte varit 
klar förrän 2020. 
 
Min mamma, för att du är så stolt över mig och visar det. 
 
Min pappa, för att du är den enda som egentligen verkligen vill läsa denna 
bok. 
 
 
This thesis is supported by grants from  
 
The Swedish Foundation for Strategic Research, the Swedish Heart and 
Lung Foundation, LUA/ALF (agreement concerning research and 
education of doctors), Swedvasc, the Swedish Stroke Association, the 
HTA-centre at Sahlgrenska University Hospital and grants from Region 
Västra Götaland. 
                                                 Optimal Timing of Surgical Treatment 
   
58…,,,. 
References 
1. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. 
Worldwide stroke incidence and early case fatality reported in 56 
population-based studies: a systematic review. Lancet neurology. 
2009;8(4):355-369. 
2. Rosengren A, Giang KW, Lappas G, Jern C, Toren K, Bjorck L. 
Twenty-four-year trends in the incidence of ischemic stroke in 
Sweden from 1987 to 2010. Stroke. 2013;44(9):2388-2393. 
3. Årsrapport-Riksstroke. http://www.riksstroke.org/wp-
content/uploads/2017/07/RiksstrokeÅrsrapport2016-web.pdf. 
2016, 2017. 
4. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. 
Classification and natural history of clinically identifiable 
subtypes of cerebral infarction. Lancet. 1991;337(8756):1521-
1526. 
5. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by 
subtype of ischemic stroke in population-based incidence studies. 
Neurology. 2004;62(4):569-573. 
6. Flaherty ML, Kissela B, Khoury JC, et al. Carotid artery stenosis 
as a cause of stroke. Neuroepidemiology. 2013;40(1):36-41. 
7. DeBakey ME. Successful carotid endarterectomy for 
cerebrovascular insufficiency. Nineteen-year follow-up. Jama. 
1975;233(10):1083-1085. 
8. Easton JD. History of carotid endarterectomy then and now: 
personal perspective. Stroke. 2014;45(6):e101-103. 
9. Randomised trial of endarterectomy for recently symptomatic 
carotid stenosis: final results of the MRC European Carotid 
Surgery Trial (ECST). Lancet. 1998;351(9113):1379-1387. 
10. Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid 
endarterectomy in patients with symptomatic moderate or severe 
stenosis. North American Symptomatic Carotid Endarterectomy 
Trial Collaborators. N Engl J Med. 1998;339(20):1415-1425. 
11. Naylor AR. MC. Carotid artery surgery-a problem based 
approach. WB Saunders; 2000. 
12. Rothwell PM. Effective stroke prevention in patients with 
                                                 Optimal Timing of Surgical Treatment 
   
59…,,,. 
symptomatic carotid stenosis. Cerebrovascular diseases. 2004;17 
Suppl 1:89-104. 
13. Rothwell PM, Gibson R, Warlow CP. Interrelation between 
plaque surface morphology and degree of stenosis on carotid 
angiograms and the risk of ischemic stroke in patients with 
symptomatic carotid stenosis. On behalf of the European Carotid 
Surgery Trialists' Collaborative Group. Stroke. 2000;31(3):615-
621. 
14. van Dijk AC, Truijman MT, Hussain B, et al. Intraplaque 
Hemorrhage and the Plaque Surface in Carotid Atherosclerosis: 
The Plaque At RISK Study (PARISK). AJNR Am J Neuroradiol. 
2015;36(11):2127-2133. 
15. Langley SR, Willeit K, Didangelos A, et al. Extracellular matrix 
proteomics identifies molecular signature of symptomatic carotid 
plaques. J Clin Invest. 2017;127(4):1546-1560. 
16. Coull AJ, Lovett JK, Rothwell PM, Oxford Vascular S. Population 
based study of early risk of stroke after transient ischaemic attack 
or minor stroke: implications for public education and 
organisation of services. Bmj. 2004;328(7435):326. 
17. Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation 
and refinement of scores to predict very early stroke risk after 
transient ischaemic attack. Lancet. 2007;369(9558):283-292. 
18. Merwick A, Albers GW, Amarenco P, et al. Addition of brain and 
carotid imaging to the ABCD(2) score to identify patients at early 
risk of stroke after transient ischaemic attack: a multicentre 
observational study. Lancet neurology. 2010;9(11):1060-1069. 
19. Song B, Fang H, Zhao L, et al. Validation of the ABCD3-I score 
to predict stroke risk after transient ischemic attack. Stroke. 
2013;44(5):1244-1248. 
20. Johnston SC, Easton JD, Farrant M, et al. Platelet-oriented 
inhibition in new TIA and minor ischemic stroke (POINT) trial: 
rationale and design. Int J Stroke. 2013;8(6):479-483. 
21. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute 
minor stroke or transient ischemic attack. N Engl J Med. 
2013;369(1):11-19. 
22. Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: 
a meta-analysis. Stroke. 2003;34(10):2475-2481. 
23. Strazzullo P, D'Elia L, Cairella G, Garbagnati F, Cappuccio FP, 
Scalfi L. Excess body weight and incidence of stroke: meta-
                                                 Optimal Timing of Surgical Treatment 
   
60…,,,. 
analysis of prospective studies with 2 million participants. Stroke. 
2010;41(5):e418-426. 
24. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering 
drugs in the prevention of cardiovascular disease: meta-analysis of 
147 randomised trials in the context of expectations from 
prospective epidemiological studies. Bmj. 2009;338:b1665. 
25. Neal B, MacMahon S, Chapman N, Blood Pressure Lowering 
Treatment Trialists C. Effects of ACE inhibitors, calcium 
antagonists, and other blood-pressure-lowering drugs: results of 
prospectively designed overviews of randomised trials. Blood 
Pressure Lowering Treatment Trialists' Collaboration. Lancet. 
2000;356(9246):1955-1964. 
26. Bond R, Narayan SK, Rothwell PM, Warlow CP, European 
Carotid Surgery Trialists' Collaborative G. Clinical and 
radiographic risk factors for operative stroke and death in the 
European carotid surgery trial. Eur J Vasc Endovasc Surg. 
2002;23(2):108-116. 
27. Rothwell PM, Howard SC, Spence JD, Carotid Endarterectomy 
Trialists C. Relationship between blood pressure and stroke risk in 
patients with symptomatic carotid occlusive disease. Stroke. 
2003;34(11):2583-2590. 
28. Berwanger O, Le Manach Y, Suzumura EA, et al. Association 
between pre-operative statin use and major cardiovascular 
complications among patients undergoing non-cardiac surgery: 
the VISION study. Eur Heart J. 2016;37(2):177-185. 
29. Heyer EJ, Mergeche JL, Bruce SS, et al. Statins reduce neurologic 
injury in asymptomatic carotid endarterectomy patients. Stroke. 
2013;44(4):1150-1152. 
30. Kennedy J, Quan H, Buchan AM, Ghali WA, Feasby TE. Statins 
are associated with better outcomes after carotid endarterectomy 
in symptomatic patients. Stroke. 2005;36(10):2072-2076. 
31. Merwick A, Albers GW, Arsava EM, et al. Reduction in early 
stroke risk in carotid stenosis with transient ischemic attack 
associated with statin treatment. Stroke. 2013;44(10):2814-2820. 
32. Committee CS. A randomised, blinded, trial of clopidogrel versus 
aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE 
Steering Committee. Lancet. 1996;348(9038):1329-1339. 
33. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal 
A. European Stroke Prevention Study. 2. Dipyridamole and 
                                                 Optimal Timing of Surgical Treatment 
   
61…,,,. 
acetylsalicylic acid in the secondary prevention of stroke. J Neurol 
Sci. 1996;143(1-2):1-13. 
34. Group ES, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, 
Algra A. Aspirin plus dipyridamole versus aspirin alone after 
cerebral ischaemia of arterial origin (ESPRIT): randomised 
controlled trial. Lancet. 2006;367(9523):1665-1673. 
35. King A, Bath PM, Markus HS. Clopidogrel versus dipyridamole 
in addition to aspirin in reducing embolization detected with 
ambulatory transcranial Doppler: a randomized trial. Stroke. 
2011;42(3):650-655. 
36. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release 
dipyridamole versus clopidogrel for recurrent stroke. N Engl J 
Med. 2008;359(12):1238-1251. 
37. Brott TG, Halperin JL, Abbara S, et al. 2011 
ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/
SIR/SNIS/SVM/SVS guideline on the management of patients 
with extracranial carotid and vertebral artery disease: executive 
summary: a report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice 
Guidelines, and the American Stroke Association, American 
Association of Neuroscience Nurses, American Association of 
Neurological Surgeons, American College of Radiology, 
American Society of Neuroradiology, Congress of Neurological 
Surgeons, Society of Atherosclerosis Imaging and Prevention, 
Society for Cardiovascular Angiography and Interventions, 
Society of Interventional Radiology, Society of 
NeuroInterventional Surgery, Society for Vascular Medicine, and 
Society for Vascular Surgery. J Am Coll Cardiol. 
2011;57(8):1002-1044. 
38. Shahidi S, Owen-Falkenberg A, Gottschalksen B, Ellemann K. 
Risk of early recurrent stroke in symptomatic carotid stenosis after 
best medical therapy and before endarterectomy. Int J Stroke. 
2016;11(1):41-51. 
39. Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy 
with clopidogrel and aspirin in symptomatic carotid stenosis 
evaluated using doppler embolic signal detection: the Clopidogrel 
and Aspirin for Reduction of Emboli in Symptomatic Carotid 
Stenosis (CARESS) trial. Circulation. 2005;111(17):2233-2240. 
40. Batchelder A, Hunter J, Cairns V, Sandford R, Munshi A, Naylor 
                                                 Optimal Timing of Surgical Treatment 
   
62…,,,. 
AR. Dual Antiplatelet Therapy Prior to Expedited Carotid Surgery 
Reduces Recurrent Events Prior to Surgery without Significantly 
Increasing Peri-operative Bleeding Complications. Eur J Vasc 
Endovasc Surg. 2015;50(4):412-419. 
41. Jones DW, Goodney PP, Conrad MF, et al. Dual antiplatelet 
therapy reduces stroke but increases bleeding at the time of carotid 
endarterectomy. Journal of vascular surgery. 2016;63(5):1262-
1270 e1263. 
42. Rothwell PM, Eliasziw M, Gutnikov SA, et al. Analysis of pooled 
data from the randomised controlled trials of endarterectomy for 
symptomatic carotid stenosis. Lancet. 2003;361(9352):107-116. 
43. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ, 
Carotid Endarterectomy Trialists C. Endarterectomy for 
symptomatic carotid stenosis in relation to clinical subgroups and 
timing of surgery. Lancet. 2004;363(9413):915-924. 
44. Writing G, Naylor AR, Ricco JB, et al. Management of 
Atherosclerotic Carotid and Vertebral Artery Disease: 2017 
Clinical Practice Guidelines of the European Society for Vascular 
Surgery (ESVS). Eur J Vasc Endovasc Surg. 2017. 
45. Cao P, De Rango P, Cieri E, Giordano G. Eversion versus 
conventional endarterectomy. Semin Vasc Surg. 2004;17(3):236-
242. 
46. Crawford RS, Chung TK, Hodgman T, Pedraza JD, Corey M, 
Cambria RP. Restenosis after eversion vs patch closure carotid 
endarterectomy. Journal of vascular surgery. 2007;46(1):41-48. 
47. Socialstyrelsen. Nationella riktlinjer för strokesjukvård. In: 
Socialstyrelsen, ed2009. 
48. Department_of_Health. The National Stroke Strategy. .  
<http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/
PublicationsPolicyAndGuidance/DH_081062>, Accessed 
January 11,  2012. 
49. Rothwell PM, Giles MF, Chandratheva A, et al. Effect of urgent 
treatment of transient ischaemic attack and minor stroke on early 
recurrent stroke (EXPRESS study): a prospective population-
based sequential comparison. Lancet. 2007;370(9596):1432-1442. 
50. Bonifati DM, Lorenzi A, Ermani M, et al. Carotid stenosis as 
predictor of stroke after transient ischemic attacks. J Neurol Sci. 
2011;303(1-2):85-89. 
51. Fairhead JF, Mehta Z, Rothwell PM. Population-based study of 
                                                 Optimal Timing of Surgical Treatment 
   
63…,,,. 
delays in carotid imaging and surgery and the risk of recurrent 
stroke. Neurology. 2005;65(3):371-375. 
52. Johansson EP, Arnerlov C, Wester P. Risk of recurrent stroke 
before carotid endarterectomy: The ANSYSCAP study. Int J 
Stroke. 2012. 
53. Ois A, Cuadrado-Godia E, Rodriguez-Campello A, Jimenez-
Conde J, Roquer J. High risk of early neurological recurrence in 
symptomatic carotid stenosis. Stroke. 2009;40(8):2727-2731. 
54. Rantner B, Schmidauer C, Knoflach M, Fraedrich G. Very Urgent 
Carotid Endarterectomy Does Not Increase the Procedural Risk. 
Eur J Vasc Endovasc Surg. 2014. 
55. Sharpe R, Sayers RD, London NJ, et al. Procedural risk following 
carotid endarterectomy in the hyperacute period after onset of 
symptoms. Eur J Vasc Endovasc Surg. 2013;46(5):519-524. 
56. Tsantilas P, Kuehnl A, Konig T, et al. Short Time Interval 
Between Neurologic Event and Carotid Surgery Is Not Associated 
With an Increased Procedural Risk. Stroke. 2016;47(11):2783-
2790. 
57. Mayberg MR, Wilson SE, Yatsu F, et al. Carotid endarterectomy 
and prevention of cerebral ischemia in symptomatic carotid 
stenosis. Veterans Affairs Cooperative Studies Program 309 
Trialist Group. Jama. 1991;266(23):3289-3294. 
58. Troeng T, Malmstedt J, Bjorck M. External validation of the 
Swedvasc registry: a first-time individual cross-matching with the 
unique personal identity number. Eur J Vasc Endovasc Surg. 
2008;36(6):705-712. 
59. Venermo M, Lees T. International Vascunet Validation of the 
Swedvasc Registry. Eur J Vasc Endovasc Surg. 2015;50(6):802-
808. 
60. Sharpe RY, Dennis MJ, Nasim A, et al. Dual antiplatelet therapy 
prior to carotid endarterectomy reduces post-operative 
embolisation and thromboembolic events: post-operative 
transcranial Doppler monitoring is now unnecessary. Eur J Vasc 
Endovasc Surg. 2010;40(2):162-167. 
61. Shahidi S, Owen-Falkenberg A, Hjerpsted U, Rai A, Ellemann K. 
Urgent best medical therapy may obviate the need for urgent 
surgery in patients with symptomatic carotid stenosis. Stroke. 
2013;44(8):2220-2225. 
62. Stromberg S, Nordanstig A, Bentzel T, Osterberg K, Bergstrom 
                                                 Optimal Timing of Surgical Treatment 
   
64…,,,. 
GM. Risk of early recurrent stroke in symptomatic carotid 
stenosis. Eur J Vasc Endovasc Surg. 2015;49(2):137-144. 
63. Kashiwazaki D, Yoshimoto T, Mikami T, et al. Identification of 
high-risk carotid artery stenosis: motion of intraplaque contents 
detected using B-mode ultrasonography. J Neurosurg. 
2012;117(3):574-578. 
64. Marnane M, Ni Chroinin D, Callaly E, et al. Stroke recurrence 
within the time window recommended for carotid endarterectomy. 
Neurology. 2011;77(8):738-743. 
65. Rerkasem K, Rothwell PM. Systematic review of the operative 
risks of carotid endarterectomy for recently symptomatic stenosis 
in relation to the timing of surgery. Stroke. 2009;40(10):e564-572. 
66. Rantner B, Kollerits B, Schmidauer C, et al. Carotid 
endarterectomy within seven days after the neurological index 
event is safe and effective in stroke prevention. Eur J Vasc 
Endovasc Surg. 2011;42(6):732-739. 
67. De Rango P, Brown MM, Chaturvedi S, et al. Summary of 
Evidence on Early Carotid Intervention for Recently Symptomatic 
Stenosis Based on Meta-Analysis of Current Risks. Stroke. 
2015;46(12):3423-3436. 
68. Stromberg S, Gelin J, Osterberg T, et al. Very urgent carotid 
endarterectomy confers increased procedural risk. Stroke. 
2012;43(5):1331-1335. 
69. Loftus IM, Paraskevas KI, Johal A, et al. Editor's Choice - Delays 
to Surgery and Procedural Risks Following Carotid 
Endarterectomy in the UK National Vascular Registry. Eur J Vasc 
Endovasc Surg. 2016;52(4):438-443. 
70. Avgerinos ED, Farber A, Abou Ali AN, et al. Early carotid 
endarterectomy performed 2 to 5 days after the onset of neurologic 
symptoms leads to comparable results to carotid endarterectomy 
performed at later time points. Journal of vascular surgery. 2017. 
71. Geraghty PJ, Brothers TE, Gillespie DL, et al. Preoperative 
symptom type influences the 30-day perioperative outcomes of 
carotid endarterectomy and carotid stenting in the Society for 
Vascular Surgery Vascular Registry. Journal of vascular surgery. 
2014;60(3):639-644. 
72. Barbetta I, Carmo M, Mercandalli G, et al. Outcomes of urgent 
carotid endarterectomy for stable and unstable acute neurologic 
deficits. Journal of vascular surgery. 2014;59(2):440-446. 
                                                 Optimal Timing of Surgical Treatment 
   
65…,,,. 
73. Capoccia L, Sbarigia E, Speziale F, et al. The need for emergency 
surgical treatment in carotid-related stroke in evolution and 
crescendo transient ischemic attack. Journal of vascular surgery. 
2012;55(6):1611-1617. 
74. Chisci E, Pigozzi C, Troisi N, et al. "Thirty-day neurologic 
improvement associated with early versus delayed carotid 
endarterectomy in symptomatic patients". Annals of vascular 
surgery. 2015;29(3):435-442. 
75. Mussa FF, Aaronson N, Lamparello PJ, et al. Outcome of carotid 
endarterectomy for acute neurological deficit. Vasc Endovascular 
Surg. 2009;43(4):364-369. 
76. Tsivgoulis G, Krogias C, Georgiadis GS, et al. Safety of early 
endarterectomy in patients with symptomatic carotid artery 
stenosis: an international multicenter study. European journal of 
neurology : the official journal of the European Federation of 
Neurological Societies. 2014;21(10):1251-1257, e1275-1256. 
77. Nordanstig A, Rosengren L, Stromberg S, et al. Editor's Choice - 
Very Urgent Carotid Endarterectomy is Associated with an 
Increased Procedural Risk: The Carotid Alarm Study. Eur J Vasc 
Endovasc Surg. 2017;54(3):278-286. 
78. Ferrero E, Ferri M, Viazzo A, et al. A Retrospective Study on 
Early Carotid Endarterectomy within 48 Hours after Transient 
Ischemic Attack and Stroke in Evolution. Annals of vascular 
surgery. 2014;28(1):227-238. 
79. Gajin P, Radak D, Tanaskovic S, Babic S, Nenezic D. Urgent 
carotid endarterectomy in patients with acute neurological 
ischemic events within six hours after symptoms onset. Vascular. 
2014;22(3):167-173. 
80. Liu L, Wong KS, Leng X, et al. Dual antiplatelet therapy in stroke 
and ICAS: Subgroup analysis of CHANCE. Neurology. 
2015;85(13):1154-1162. 
81. Rothwell P, Warlow C. Is self-audit reliable? Lancet. 
1995;346(8990):1623. 
82. Naylor AR. Time is brain: an update. Expert Rev Cardiovasc Ther. 
2015;13(10):1111-1126. 
 
